Meet the Team Behind the Work
Our flexible, client-focused structure means that when you work with Medicus Economics,
you have access to all of the capabilities of our diverse group of health economics experts.
Marric G. Buessing, PhD
PRINCIPAL
marric.buessing@medicuseconomics.com
Dr. Buessing has extensive consulting and analytical experience in the healthcare industry. Prior to joining Medicus, Dr. Buessing was a Manager at Analysis Group where she supported academic experts on matters related to pharmaceutical litigation which included analyses related to economic damages, cost-effectiveness models, and systematic literature reviews. She has over 10 years of experience working with various healthcare data sources including claims data, clinical trial data, and patient/physician/payer surveys. Dr. Buessing’s academic research has focused on the intersection of regulatory policy and health and safety outcomes. She received both her bachelor’s degree in Economics and International Relations and a Ph.D. in Economics from Boston University.
Elizabeth Chertavian, MBA
PRINCIPAL
elizabeth.chertavian@medicuseconomics.com
Ms. Chertavian is a Principal at Medicus specializing in providing data analytics and consulting services to the healthcare industry. She has worked within the pharmaceutical and biotech industries to support commercial and market access activities for a wide variety of products. Her work centers around HEOR strategy and economic decision modeling, including HTA engagements, cost-effectiveness models, budget impact analyses, natural-history models, and real-world evidence generation. Prior to joining Medicus, she spent seven years at Analysis Group, where her work specifically focused on litigations involving pricing and contract disputes, false claims act investigations and controlled substance monitoring, where she supported academic experts in their analysis of claims data and prescription drug data. Ms. Chertavian received her bachelor’s degree in Mathematics and French from Bowdoin College and her M.B.A. from Harvard Business School.
Matthew R. Davis, MA
PRINCIPAL
matthew.davis@medicuseconomics.com
Mr. Davis has extensive analytical experience in health outcomes research and pharmaceutical litigation, and has conducted academic studies on issues of health policy reform. He has worked with clients and key opinion leaders to assess the value and effectiveness of novel healthcare interventions and treatment strategies from the patient, payer, and societal perspective. This research has involved applying a wide array of econometric methods to databases of all types, and using a diversity of modeling and simulation techniques to project expected outcomes. Mr. Davis received a bachelor’s degree in Economics and Mathematics from Williams College and a master’s degree in Economics from Boston College, specializing in Econometrics and Labor Economics.
Andrew J. Epstein, PhD, MPP
PRINCIPAL
andrew.epstein@medicuseconomics.com
Dr. Epstein has over two decades of experience conducting empirical health economics and health services research studies. His research program combines novel data, careful application of analytic methods and an appreciation for the institutional context to answer important questions across a range of clinical settings. This work has resulted in over 80 publications in top peer-reviewed journals across medicine, outcomes research, health services research, and health economics. Previously, Dr. Epstein was on faculty at the University of Pennsylvania Perelman School of Medicine and the Yale School of Public Health. He received a bachelor’s degree in Computer Science from Amherst College, a master’s degree in Health Policy from Georgetown University, and a Ph.D. in Applied Economics and Managerial Science from the University of Pennsylvania Wharton School of Business.
Robert Espinosa, MBA
PRINCIPAL
robert.espinosa@medicuseconomics.com
Mr. Espinosa has provided consulting services for clients in the healthcare, financial services, and high-tech manufacturing industries through his work at Medicus and, previously, Analysis Group. He has extensive experience conducting empirical and quantitative analyses in a variety of settings that include conducting health outcomes research, developing pricing and contracting strategies for pharmaceutical manufacturers, and supporting academic experts testifying as part of antitrust litigations. Mr. Espinosa received an M.B.A. from the Haas School of Business, University of California Berkeley and bachelor’s degree in economics from Boston College.
Scott J. Johnson, PhD, MHA
PRINCIPAL
scott.johnson@medicuseconomics.com
Dr. Johnson is a health economist with over fifteen years of experience in econometric analyses of large databases, discrete choice analysis and design of prospective experiments, modeling, pricing, and policy analysis. Prior to joining Medicus, he co-founded and managed a firm specializing in cost-effectiveness analysis for four years and worked at the Analysis Group for six years. Dr. Johnson earned his undergraduate degree in History at the University of Virginia, his MHA from the Medical College of Virginia, and his Ph.D. in Applied Economics and Managerial Science from the University of Pennsylvania Wharton School of Business.
Thomas O’Connell, MA
PRINCIPAL
thomas.oconnell@medicuseconomics.com
Mr. O’Connell’s experience spans the healthcare and consumer-technology industries. He has provided economic-consulting services addressing commercial/market-access strategies to various large pharmaceutical corporations, and has conducted economic analyses informing litigation between major Silicon Valley technology corporations.
In his healthcare work, Mr. O’Connell has focused on optimization of market-access/reimbursement strategy, and on economic evaluations for health-technology assessment (HTA). His models have been used by pharmaceutical corporations in establishing strategies concerning international reference pricing, foreign market access and reimbursement, and optimal launch-price and discounting strategies in the US. In support of products undergoing HTA (primarily for ultra-rare diseases), he has conducted cost-effectiveness and budget-impact analyses and/or authored technical reports for HTA submissions in 15+ markets. He has engaged in-person with HTA agencies in scoping/ committee meetings (including CADTH, NCPE, ZIN, and SMC), and served as the health-economics advisor in negotiations of a Managed Access Agreement (MAA) between a client and NICE/NHS England for an ultra-rare-disease product, which resulted in a “first of a kind” MAA providing access to therapy for pediatric-onset hypophosphatasia patients with severe unmet need in England. In addition, Mr. O’Connell has advised clients through review by the Institute for Clinical and Economic Review (ICER) in the US, and presented to cross-functional groups at client companies on HEOR theory and methods and their role in supporting market access.
Hélène Parisé, MA
PRINCIPAL
helene.parise@medicuseconomics.com
Ms. Parisé specializes in the application of statistics, econometrics and applied microeconomics to litigation and health economics. Her area of expertise includes large retrospective database/claims analyses; cost-effectiveness and budget impact modeling; treatment patterns and medication compliance studies; clinical trial data analyses; and assessment of direct medical and indirect productivity costs of a disease burden. She has conducted research on a broad range of diseases and conditions including hepatitis C, overactive bladder, Crohn’s disease, postpartum depression, hypertension, epilepsy, multiple sclerosis, diabetes, schizophrenia, and anemia. Her research resulted in presentations at health care conferences and publications in several peer-reviewed journals, including Neurology, Hypertension, Advances in Therapy, Journal of Medical Economics, Journal of the Neurological Sciences, PharmacoEconomics Open, and Journal of Diabetes Science and Technology. Ms. Parisé earned her Bachelor’s and Master’s Degrees in Economics at Laval University.
Cheryl Steward, MA
PRINCIPAL
cheryl.steward@medicuseconomics.com
For more than 25 years, Ms. Steward has worked closely with clients to design and implement market access and commercialization strategies. Before joining Medicus, Ms. Steward was an independent consultant to life science companies. Prior to that she held various senior management positions within Covance Market Access, including Vice President of Innovation and Implementation, Vice President Market Access Consulting and Patient Support Services, and as a member of the Executive Management Team. Ms. Steward received an M.P.A. with a concentration in Policy Analysis from The George Washington University and a B.A. from Temple University.
Warren Stevens, PhD
PRINCIPAL
warren.stevens@medicuseconomics.com
Mr. Stevens has been conducting empirical health economics and health policy research studies for twenty years in diverse settings covering four continents. His research experience includes health policy and health systems research, cost-effectiveness modeling, development of new methodologies in value assessment and health outcome measurement. His research has been published in leading medical, health services research, and economics journals, including the Lancet, the British Medical Journal, Health Affairs, Health Services Research, Health Economics, the American Journal of Managed Care, and PLOS Medicine.
Mr. Stevens has a diverse set of research interest that span from greater reflection of heterogeneity of effect in reporting of cost-effectiveness, the estimation and application of time-varying cost-effectiveness and the evolution of health utility measures to better reflect patients’ preferences. He received a bachelor’s degree in Economics & Philosophy from Royal Holloway College, a master’s degree in Health Services Research and a Ph.D. in Health Economics from the London School of Hygiene and Tropical Medicine.
Si-Tien (Mary) Wang, MS
PRINCIPAL
sitien.wang@medicuseconomics.com
Ms. Wang has conducted and directed a wide range of investigations in health economics and outcomes research, including comparative effectiveness, direct and indirect resource utilization and costs, work loss, quality of life, treatment pattern, disease prevalence, and adverse events across therapeutic area. Her research has involved data from clinical trials, medical records review, automated health insurance claims, systematic literature review, and patient/physician/payer surveys. Ms. Wang received a B.A. in Economics and Neuroscience from Wellesley College and a M.S. in Health Policy and Management from Harvard School of Public Health.
